Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis

Medical Mycology

Volumn 47, Issue 8, 2009, Pages 802-807

  Mouton, J W ^a   Te Dorsthorst, D T A ^a,b,c   Meis, J F G M ^a   Verweij, P E ^b,c  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SLINGELAND HOSPITAL   (Netherlands)

Author keywords

Amphotericin B; Animal model; Aspergillus

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG FORMULATION; FEMALE; FUNGAL VIRULENCE; IN VIVO STUDY; MORTALITY; MOUSE; NONHUMAN; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; DISEASE MODEL; MICROBIOLOGY; NEUTROPENIA; NONLINEAR SYSTEM; SURVIVAL;

ANIMALIA; ASPERGILLUS; ASPERGILLUS FUMIGATUS; MURINAE; MUS;

AMPHOTERICIN B; ANIMALS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; NEUTROPENIA; NONLINEAR DYNAMICS; SURVIVAL ANALYSIS;

EID: 73649095124     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780802672644     Document Type: Article

References (28)

1. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 ( Suppl. 2 ): S133- 144.
2. Leenders AC, de Marie S. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 1996; 10: 1570-1575.
3. Bakker-Woudenberg IA. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int J Antimicrob Agents 2002; 19: 299-311.
4. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006; 50: 2122-2131.
5. van Etten EW, Otte-Lambillion M, van Vianen W, ten Kate MT, Bakker-Woudenberg AJ. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35: 509-519.
6. Adedoyin A, Swenson CE, Bolcsak LE, et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000; 44: 2900-2902.
7. Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46: 828-833.
8. Lewis RE, Liao G, Hou J, et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51: 1253-1258.
9. Takemoto K, Yamamoto Y, Ueda Y, et al. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 724-731.
10. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006; 50: 3418-3423.
11. van Etten EW, ten Kate MT, Stearne LE, Bakker-Woudenberg IA. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995; 39: 1954-1958.
12. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-3481.
13. NCCLS. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. 2002 ; 28: 1-9.
14. te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW. Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. Antimicrob Agents Chemother 2005; 49: 3341-3346.
15. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41: 733-738.
16. Nolting A, Derendorf H. Pharmacokinetic/pharmacodynamic modelling of antibiotics. In: Derendorf H, Hochhaus G (eds). Handbook of Pharmacokinetic/ Pharmacodynamic Correlation. Boca Raton, FL: CRC Press, 1995: 363-388.
17. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003; 47: 1179-1186. (Pubitemid 36368572)
18. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol 2007; 45: 109-111.
19. Mouton JW. Pharmacokinetics and pharmacodynamics of azoles. In: Nightingale C, Ambrose PG, Drusano GL, Mukisawa T (eds). Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York : Informa Health Care Inc, 2007: 327-354.
20. Wiederhold NP, Tam VH, Chi J, et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 469-473.
21. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J Antimicrob Chemother 1996; 38: 215-225.
22. Van Etten EW, Stearne-Cullen LE, ten Kate M, Bakker-Woudenberg IA. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrob Agents Chemother 2000; 44: 540-545.
23. Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations-Fungizone, amphotec (Amphocil), AmBisome, and Abelcet-against systemic murine aspergillosis. Antimicrob Agents Chemother 2004; 48: 1047-1050.
24. Dotis J, Simitsopoulou M, Dalakiouridou M, et al. Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus Antimicrob Agents Chemother 2006; 50: 868-873.
25. Dotis J, Simitsopoulou M, Dalakiouridou M, et al. Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani : comparison with Aspergillus fumigatus. J Antimicrob Chemother 2008; 61: 810-817.
26. Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005; 49: 1397-1403.
27. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-216.
28. Becker MJ, de Marie S, Fens MH, et al. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J Antimicrob Chemother 2002; 49: 813-820.